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Abstract 
Review on TWIST2, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: DERMO1, FFDD3, SETLSS, 
bHLHa39 
HGNC (Hugo): TWIST2 
Location: 2q37.3 
Note 
The gene maps on the long arm of Chromosome 2 
at position q37.3 (Perrin-Schmitt et al., 1997). 
 
DNA/RNA 
Description 
This gene is localized at chromosome 2q37.3 
(Perrin-Schmitt et al., 1997) and has 2 exons (Šošic 
et al., 2003). 
Transcription 
TWIST2 DNA sequence contains 2 exons separated 
by a large intron, with the entire coding region 
located in exon 1 (Šošic et al., 2003). Two 
transcript variants encoding the same protein have 
been described: variant 1 of 1434 bp and variant 2 
of 1186 bp. Both variants encode a same protein but 
have different 3' UTR (NCBI). 
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Structure of TWIST2 protein. The protein domains and their length (indicated by number of limiting residues) are reported. 
TWIST2 contains 2 nuclear localization signals, a basic helix loop helix (bHLH) domain and a TWIST box domain (Modified from 
Gong and Li, 2002). 
 
Pseudogene 
No pseudogene of TWIST2 is known. 
Protein 
Description 
The TWIST2 gene encodes a 160 aminoacid protein 
with a predicted molecular weight of 19 kDa (Li et 
al., 1995; Lee et al., 2000; Gong and Li, 2002). 
TWIST2 structure includes 2 nuclear localization 
signals at the N-terminus (aa 31-34, aa 49-53), a 
basic helix-loop-helix (bHLH) domain (aa 66-117) 
and a C-terminal TWIST box region (aa 141-160) 
(Gong and Li, 2002). 
Post transcriptional phosphorylation at Ser55 is 
predicted for both human and rodent protein 
(phosphosite). The bHLH domain includes highly 
conserved Thr and Ser residues whose 
posphorylation has been demonstrated to affect 
dimer formation and DNA binding affinity in other 
TWIST family members (Firulli et al., 2005; Firulli 
and Conway, 2008). 
Expression 
TWIST2 is involved in mesodermal patterning and 
in differentiation of multiple cell lineages including 
muscle, cartilage, osteogenic, adipogenic and 
myeloid cells (Lee et al., 2000; Gong and Li, 2002; 
Lee et al., 2003; Sharabi et al., 2008). In human 
embryonic tissues TWIST2 protein is detectable in 
early chondroblast cells in cartilage plate and 
surrounding mesenchymal cells, especially near the 
tip of the digits (Lee et al., 2000). In the skin, it is 
expressed early in the undifferentiated 
mesenchymal layer beneath the epidermis that will 
develop into dermis (Lee et al., 2000). TWIST2 is 
expressed in myeloid progenitors (Sharabi et al., 
2008). In adult tissues, TWIST2 is expressed in the 
bone marrow (Ishikawa et al., 2013). A low level of 
expression has been reported in glands and tubules 
(Lee et al., 2000) as well as liver, muscle, pancreas, 
and adipose tissue (Pettersson et al., 2010). It 
should be pointed out that many antibodies used to 
detect the expression of TWIST proteins recognize 
both members of the family, making it hard to 
actually assess the specific contribution of each 
protein. 
Localisation 
Nuclear in embryonic tissues, predominantly 
cytoplasmic in adult tissues (Lee et al., 2000). 
Function 
TWIST2 is a transcription factor belonging to the 
bHLH (basic helix loop helix) family (Li et al., 
1995; Lee et al., 2000). bHLH proteins form homo- 
or heterodimers with other bHLH family members 
and, as dimers, bind DNA through the bHLH 
domain at cis regulatory motifs, termed E-box 
(CANNTG), leading to either activation or 
inhibition of transcription (Murre et al., 1989; 
Franco et al., 2011b). The specificity of the dimers 
depends on several factors: partner choice, 
phosphorylation, other protein-protein interactions 
and spatial-temporal expression (Murre et al., 1989; 
Franco et al., 2011b). The partner choice depends 
mainly on the availability and on the 
phosphorylation status of the partner (Firulli and 
Conway, 2008). 
TWIST2, similar to TWIST1, may also control 
gene expression by epigenetic modulation of the 
promoter: TWIST1-2 interacts with and recruits 
histone acetyl transferases/histone deacetylases to 
the promoter regulatory region, resulting in 
transcriptional repression through histone 
modification (Hamamori et al., 1999; Gong and Li, 
2002; Lee et al., 2003). 
Role in embryonic development 
Murine Twist2 was identified through yeast-two-
hybrid screen (Staudinger et al., 1993) and it was 
named Dermo1 for its expression pattern in the 
dermis of mouse embryo (Li et al., 1995). Dermo1 
was later renamed Twist2 (Šošic et al., 2003) based 
on its high homology and overlapping expression 
pattern with Twist1 (Li et al., 1995; Lee et al., 
2000; ŠoŠic et al., 2003). During mouse 
embryogenesis Twist2 displays a spatial expression 
pattern similar to Twist1, but temporally delayed 
(Li et al., 1995; Lee et al., 2000). Twist2 is 
expressed at a lower level in the sclerotome and 
dermatome of the somites, and in the limb buds at 
Day 10.5, and accumulates predominantly in the 
dermatome, prevertebrae, and the derivatives of the 
branchial arches by Day 13.5 (Li et al., 1995). As 
differentiation of prechondrial cells proceeds, 
Twist2 becomes restricted to the perichondrium (Li 
et al., 1995). In the dermis, expression increases 
continuously through Day 17.5, is detectable in 
newborns but is then downregulated in adult tissues 
(Li et al., 1995). An analogous role has been 
reported for Twist2 in avian limb outgrowth and 
patterning (Wade et al., 2012) as well as skin 
development (Scaal et al., 2001). 
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TWIST2 plays an important role in early bone 
development, acting as a negative regulator of 
osteoblast differentiation. Indeed, TWIST2 
represses osteoblast maturation maintaining cells in 
a preosteoblast phenotype (Tamura and Noda, 
1999; Lee et al., 2000) and it inhibits bone specific 
gene expression (Zhang et al., 2008). TWIST2 is 
involved in the modulation of the activity of Runx2, 
a master regulator of osteogenic program, both at 
the transcriptional level and at the protein level 
(Bialek et al., 2004; Zhang et al., 2008). By 
interacting with Runx2, TWIST2 inhibits the 
expression of Runx2 downstream targets, thus 
blocking the osteogenesis program (Lee et al., 
2003). Runx2 can be downregulated by ERK, 
therefore ERK cooperates with TWIST2 in the 
inhibition of osteoblast differentiation (Nakamura 
et al., 2010). Insulin receptor signaling also controls 
osteoblast development by suppressing TWIST2 
(Fulzele et al., 2010; Ulrich et al., 2013). In 
osteoblast TWIST2 physically interacts with ATF4 
affecting its DNA binding function (Danciu et al., 
2012). During cranial cell development TWIST2 is 
a mediator of Wnt signaling in specifying dermal 
cell fate and suppressing the cartilage cell fate 
(Tran et al., 2010). 
TWIST2 is furthermore involved in the inhibition 
of muscle differentiation program acting as a 
transcriptional repressor of MyoD, the activation of 
which typically requires the binding of MEF2 
(Gong and Li, 2002). TWIST2 needs histone 
deacetylases (HDAC) to exert Myo-MEF2 
inhibition (Gong and Li, 2002). TWIST2 is also a 
critical regulator of adipose tissue homeostasis 
acting as a physical inhibitor of the transcription 
factor ADD1/SREBP1c, involved in adipocyte 
differentiation (Lee et al., 2003). 
TWIST2 is required for normal corneal keratocyte 
proliferation and eyelid morphogenesis. Loss of 
TWIST2 leads to corneal thinning, due to early 
cessation of proliferation of corneal stromal 
progenitors, resulting in fewer mature stromal 
keratocytes for the production of the corneal matrix 
(Weaving et al., 2010). 
In myeloid lineage development, TWIST2 inhibits 
the proliferation and the differentiation of 
granulocyte macrophage progenitors (Sharabi et al., 
2008). TWIST2-null 129/Sv mice undergo almost 
normal embryonic development but die within the 
first two weeks after birth due to cachexia and high 
levels of proinflammatory cytokines (Šošic et al., 
2003). However, the phenotype is influenced by 
genetic background. In fact TWIST2-null mice in 
the 129/C57 mixed background survive with only a 
mild disease and facial signs reminiscent of facial 
dermal dysplasia (Setleis syndrome), the human 
disease associated with germline TWIST2 
inactivating mutations (Tukel et al., 2010). 
 
Role in hematopoiesis and inflammation 
TWIST2 is constitutionally expressed in myeloid 
progenitors where negatively controls myeloid 
lineage differentiation into macrophages, 
neutrophils and basophils (Sharabi et al., 2008). 
TWIST2 regulates the function of mature myeloid 
cells by promoting the expression of the anti-
inflammatory cytokine interleukin-10 and inhibiting 
the production of pro-inflammatory cytokines 
interleukin-12 and interferon-γ (Sharabi et al., 
2008). TWIST2 expression is also induced by NF-
kB, as part of a negative feedback loop in which 
cytokines activate NF-kB and downstream 
activation of TWIST2 results in repression of NF-
kB activation (Šošic et al., 2003). 
In T lymphocytes and in immature thymocytes 
TWIST2 inhibits galectin-1-induced apoptosis, a 
process implicated in thymic negative selection 
(Koh et al., 2008; Koh et al., 2009; Merindol et al., 
2014). TWIST2 prevents NF-kB mediated 
expression of galectin receptor (CD7), therefore 
inhibiting galectin1/CD7-mediated apoptosis (Koh 
et al., 2008; Koh et al., 2009; Merindol et al., 
2014). 
Role in apoptosis and senescence 
TWIST2 antagonizes oncogene-induced cell 
failsafe programs, apoptosis and senescence. In a 
genetic screen for antiapoptotic proteins, TWIST2 
was demonstrated to protect cells from Myc and 
E1A-induced apoptosis by modulating the 
ARF/MDM2/p53 pathway (Maestro et al., 1999). 
TWIST2 overcomes oncogene-induced premature 
senescence by abrogating the transcription of 
p16Ink4A and p21Cip1, key regulators of the p53- 
and RB-dependent pathways (Ansieau et al., 2008). 
Role in oxidative stress 
TWIST2 participates in the control of reactive 
oxygen species (ROS) and in cellular response to 
oxidative stress. TWIST2 lowers the level of 
intracellular ROS and displays an antioxidant 
activity in several cell types. TWIST-driven 
inhibition of oxidative stress is involved in the 
protection of cells against c-Myc induced apoptosis 
(Floc'h et al., 2013). 
Role in stemness (cancer stem cells) 
TWIST2 mediates mesenchymal stem cell (MSC) 
self-renewal by maintaining the immature 
phenotype of human MSC and inhibiting 
osteogenesis and chondrogenesis (Isenmann et al., 
2009). In mouse, the inhibition of MSC 
differentiation induced by fibroblast growth factor 2 
(Fgf2) is strongly correlated with the upregulation 
of TWIST2 and Spry4 and with the suppression of 
Erk1/2 activation (Lai et al., 2011). TWIST2-
expressing cells exhibit an increased expression of 
stem cell markers Bmi-1, Sox2, CD24, Nanog and 
an increased capacity of self-renewal (Liu et al., 
2014). 
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Role in EMT 
TWIST2 has been involved in epithelial-
mesenchymal transition (EMT), a process by which 
cells lose epithelial characteristics and acquire a 
migratory, mesenchymal phenotype. EMT is 
associated with downregulation of epithelial 
markers, such as E-cadherin, and induction of 
mesenchymal markers, such as N-cadherin. EMT 
has an essential role in embryonic development and 
in the initial steps of tumor invasion and metastasis. 
Several bHLH transcription factors are involved in 
the regulation of EMT. TWIST2 has been 
implicated in EMT in several experimental models 
and cancer types (Tsuji et al., 2008; Katoh and 
Katoh, 2009; Ponnusamy et al., 2010; Fang et al., 
2011; Akkari et al., 2012; Amatangelo et al., 2012; 
Salnikov et al., 2012; Shimoda et al., 2012; Mao et 
al., 2012; Mao et al., 2013; Teng and Li, 2014; 
Díaz-Martín et al., 2014). A dynamic interaction 
between EMT and stemness gene programs has 
been observed in prostate and bladder cancer cell 
experimental models (Celià-Terrassa et al., 2012). 
 
Homology 
TWIST genes are evolutionary conserved from 
jellyfish to human. Duplications and deletions of 
TWIST genes occurred during vertebrate evolution 
(Germanguz et al., 2007; Gitelman, 2007). 
The human TWIST2 protein shares 98.8% amino 
acid identity to mouse and rat and 95% to chicken 
Twist2 (Lee et al., 2000). 
Within the bHLH protein family, TWIST2 displays 
the highest level of sequence similarity with 
TWIST1. The two proteins are near identical in the 
C-terminal Helix-Loop-Helix (HLH) and TWIST 
BOX domains, while they display some divergence 
in the N-terminal region (Lee et al., 2000; Gong 
and Li, 2002; Barnes and Firulli, 2009). 
Mutations 
Germinal 
TWIST2 nonsense mutations have been associated 
with Focal Facial Dermal Dyspasia type III (Setleis 
syndrome), a developmental defect characterized by 
bitemporal or pre auricolar facial dermal dysplasia 
(Tukel et al., 2010; Cervantes-Barragán et al., 2011; 
Franco et al., 2011a; Girisha et al., 2014). 
Somatic 
Missense mutations have been found in endometrial 
cancer (COSMIC). 
Implicated in 
Breast cancer 
Note 
TWIST2 overexpression has been implicated in 
breast cancer. TWIST2 protein was reported to be 
expressed in 94% of breast cancers and in 100% of 
nodal metastases. In mammary cell lines TWIST2 
ectopic overexpression induced EMT, enhanced 
cell migration, colony formation, and tumor growth 
in vivo.  
TWIST2 induced the expression of stem cell 
markers thereby increasing the abundance of a 
CD44high/CD24low subpopulation with stem-like 
self renewal capacities (Fang et al., 2011).  
Mao et al. (2012) observed TWIST2 expression, 
most frequently in ductal and in squamous cell 
breast carcinomas. Expression pattern was 
cytoplasmic in cells localized in tumor centre and in 
lymph node metastases, while TWIST2 displayed 
nuclear expression and associated with EMT 
features (fibroblast-like morphology, E-cadherin 
loss) in cells at the invasive front. TWIST2 
cytoplasmic positive expression was associated 
with advanced TNM, advanced clinical stage and 
metastasis (Mao et al., 2012). 
Cervical cancer 
Note 
Li et al. (2012) investigated TWIST2 and E-
cadherin protein expression in different stages and 
grades of cervical dysplasia and squamous cell 
carcinoma (SCC). All SCCs were positive for 
cytoplasmic TWIST2 expression, and in 87.1% 
specimens staining were also nuclear. In contrast, 
only 7.1% of healthy cervical samples showed 
weak/moderate cytoplasmic or nuclear positivity. 
TWIST2 positivity was associated with aberrant E-
Cadherin cytoplasmic localization. TWIST2 
cytoplasmic expression was associated with 
significantly increased risk of metastasis (Li et al., 
2012). 
Colorectal cancer 
Note 
TWIST2 expression was demonstrated by 
immunohistochemistry in 71% of colorectal 
cancers. The pattern of staining was mainly 
cytoplasmic and was associated with reduced E-
cadherin. Positive TWIST2 expression was 
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associated with poor disease-free and overall 
survival (Yu et al., 2013).  
Long et al. (2013) observed decreased expression of 
mir-138 in colorectal cancers compared to healthy 
tissues and provided evidence that mir-138 targeted 
TWIST2. Indeed, overexpression of TWIST2 was 
inversely correlated with mir-138 and associated 
with metastasis and poor prognosis (Long et al., 
2013). 
Ovarian cancer 
Note 
Mao et al. (2013) reported overexpression of 
TWIST2 in 16/22 ovarian tumors compared to 
healthy tissue. The high level of TWIST2 was 
positively correlated with HIF-1α. In the HO-8910 
ovarian cell line, TWIST2 overexpression protected 
cells from apoptosis under hypoxic condition 
through activation of the PI3K/AKT survival 
pathway. In a following study, the same authors 
confirmed TWIST2 overexpression in 59/84 (70%) 
ovarian cancers. The pattern of expression was both 
nuclear and cytoplasmatic, and the fraction of 
TWIST2-positive cases was increased along with 
the FIGO stage. In the ovarian cell line SKOV-3 the 
ectopic expression of TWIST2 induced EMT, β-
catenin nuclear accumulation and activation of the 
Wnt pathway (Mao et al., 2013). 
Head and Neck squamous cell 
carcinomas (HNSCC) 
Note 
TWIST2 gene expression was increased in 87% 
esophageal squamous cell carcinomas (Ansieau et 
al. 2008). In tongue squamous cell carcinomas 
overexpression of TWIST2 was detected in 45% of 
tumors and was associated with hypoxia. The 
concomitant expression of more than two of the 
markers TWIST2, HIF-1α, and SNIP1 was 
associated with poor survival (Liang et al., 2011).  
In salivary adenoid cystic carcinoma the 
coexpression of TWIST2, HIF-2α and SIP1 was 
associated with perineural invasion, local 
recurrence, distant metastasis and shorter survival 
(Zhou et al., 2012). 
In HNSCCs TWIST2 overexpression was 
correlated with high tumor grade and short survival 
in oral cavity/pharynx cancer patients. In these 
tumors, TWIST2 expression was not associated 
with EMT markers. Instead, within the N-positive 
group, identified subset of tumors with high risk of 
progression (Gasparotto et al., 2011). 
Leukemias 
Note 
In leukemias TWIST2 has oncosuppressive role. 
Raval et al. (2005) reported epigenetic silencing of 
TWIST2 in chronic lymphocytic leukemia (CLL), 
and provided evidence that expression of this 
transcription factor was related to the degree of 
promoter methylation. In this study, TWIST2 
promoter methylation was more frequent in the 
IgVH-mutated CLL subset (Raval et al., 2005). In 
acute lymphoblastic leukemia (ALL) the TWIST2 
promoter was hypermethylated in 50% of cases. In 
ALL cell lines the restoration of TWIST2 
expression reduced cell growth, induced apoptosis 
and increased sensitivity to chemotherapeutic 
agents (Thathia et al., 2012). 
Hepatocellular carcinomas (HCC) 
Note 
TWIST2 was found to be overexpressed in human 
HCCs. Ectopic expression of TWIST2 in HCC cell 
lines induced EMT, augmented cell migration, 
invasion and colony-forming abilities in vitro and 
promoted tumor growth in vivo.  
Moreover, TWIST2 promoted cancer stem-like cell 
self-renewal via upregulation of CD24 expression 
(Liu et al., 2014).  
TWIST2 was also implicated in the process of 
oncogenic transformation of primary hepatocytes 
by Hepatitis C virus (HCV).  
The viral protein NS5A either alone or in the 
context of other viral components in the course of 
infection, acted through TWIST2 activation to 
disrupt cell polarity, and, in cooperation with Ras, 
induced cell transformation and metastastatic 
spread in vivo (Akkari et al., 2012). 
Sarcomas 
Note 
By investigating the role of TWIST in soft tissue 
sarcomas, Piccinin et al. (2012) demonstrated 
overexpression of TWIST1 and TWIST2 proteins 
in 60% and in 7% of tumors, respectively. 
TWIST1/2 contributed to transformation of primary 
mesenchymal cells in vitro and to tumor growth in 
mice by antagonizing p53.  
By directly interacting with p53, TWIST1/2 
hindered p53 phosphorylation at Ser 392, thereby 
facilitating MDM2-mediated p53 degradation 
(Piccinin et al., 2012).  
In osteosarcoma TWIST2 demonstrated a tumor 
suppressive role (Ishikawa et al., 2013). In human 
osteosarcomas TWIST2 mRNA level was 
downregulated compared with bone marrow stem 
cells.  
In a murine model, TWIST2 correlated inversely 
with tumorigenic potential. The tumor suppressor 
activity of TWIST2 was correlated with the 
inhibition of the formation of a microenvironment 
favourable for tumor growth (Ishikawa et al., 2013). 
Melanomas 
Note 
TWIST2 expression was significantly increased in 
melanomas (60%) compared to their normal 
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counterparts, as well as in melanoma cell lines 
(Ansieau et al., 2008). 
TWIST1/2 inhibited premature senescence by 
abrogating p16 INK4A and p21 cip activation and 
promoted EMT in cooperation with mitogenic 
signaling activation (Ansieau et al., 2008). 
Focal facial dermal dysplasia type III, 
or Setleis syndrome 
Note 
Focal facial dermal dysplasia type III, or Setleis 
syndrome (OMIM entry 607556). The disease was 
first described in consanguineous patients in Puerto 
Rican families (Setleis et al., 1963).  
Patients exhibit bilateral temporal preauricular 
marks and other facial abnormalities, including 
absent eyelashes on both lids or multiple rows on 
the upper lids, slanted eyebrows chin clefting, and 
other nonfacial manifestations (Tukel et al., 2010, 
Cervantes-Barragán et al., 2011).  
The disease is panethnic (Tukel et al., 2010). The 
mode of inheritance of Setleis syndrome has been 
reported as autosomal recessive or autosomal 
dominant with decreased manifestations in 
heterozygotes (Tukel et al., 2010, Cervantes-
Barragán et al., 2011). 
2q37 deletion syndrome 
Note 
TWIST2 has been proposed as candidate gene of 
the 2q37 deletion syndrome due to its localization 
in the smallest deleted chromosome region (Leroy 
et al., 2013). 
Disease 
Patients exhibit facial dysmorphism and 
brachydactyly, behavioural problems, autism of 
varying severity and overweight or obesity (Leroy 
et al., 2013). 
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